Ultra fast-acting insulin (Adocia)

超速效赖脯胰岛素（Adocia）

Report date: 2022/03/31 14:57:05

Base Information

Drug NameUltra fast-acting insulin (Adocia)
Drug Alias NameBioChaperone insulin lisproBioChaperone Ultra Fast LisproBioChaperone Lispro U200BioChaperone Lispro U100Ultra-RapidInsulin +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeGermanyMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAdocia
China Registration ClassN/A

Develop Information

Active CompaniesMeitheal Pharmaceuticals IncTonghua Dongbao Pharmaceutical Co LtdNanjing King-Friend Biochemical Pharmaceutical Co Ltd
Inactive CompaniesEli Lilly And CompanyAdocia
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB04
Related LinksN/A